Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MOTRIN vs INJECTAPAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective COX-1 and COX-2 inhibitor, reducing prostaglandin synthesis.
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
Rheumatoid arthritis,Osteoarthritis,Mild to moderate pain,Primary dysmenorrhea,Fever reduction
Management of mild to moderate pain,Reduction of fever
Ibuprofen (Motrin) 200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day for acute pain, and 2400 mg/day for chronic use.
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
Terminal elimination half-life approximately 2-4 hours in adults with normal renal function; prolonged in elderly and patients with renal impairment (up to 6-8 hours). No significant accumulation occurs with regular dosing.
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Hepatic via CYP2C9 and glucuronidation; minor via CYP2C8.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Renal excretion of conjugated metabolites (approximately 70-80% as glucuronide and sulfate conjugates); less than 10% excreted unchanged. Biliary/fecal elimination accounts for about 10-20%.
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
Highly protein-bound (approximately 99%) primarily to albumin.
10-25% bound to albumin at therapeutic concentrations.
Approximately 0.1-0.2 L/kg (range 0.1-0.2 L/kg); indicative of limited tissue distribution due to high protein binding. Larger Vd in neonates (0.3-0.4 L/kg).
0.8-1.0 L/kg; suggests distribution into total body water.
Oral immediate-release: 80-100%; oral extended-release: approximately 85-90% relative to immediate-release; intravenous: 100%; topical (e.g., gel): 3-8% systemic absorption.
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
GFR 30-59 m L/min: use minimum effective dose, monitor renal function; GFR <30 m L/min: avoid use; dialysis: not removed by hemodialysis, avoid use.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
Child-Pugh Class A: no adjustment; Class B: use with caution, reduce dose by 50%; Class C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Children 6 months to 12 years: 5-10 mg/kg/dose every 6-8 hours; maximum 40 mg/kg/day, not to exceed adult maximum; for fever >39°C, 10 mg/kg/dose; available as oral suspension (100 mg/5 m L).
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
Initiate at the lowest effective dose (e.g., 200-400 mg every 6-8 hours), maximum 3200 mg/day; monitor for GI bleeding and renal impairment; avoid prolonged use due to increased cardiovascular and GI risks.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. Contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
Increased risk of cardiovascular thrombotic events; risk of serious GI adverse events including bleeding, ulceration, and perforation; renal toxicity; hypertension; anaphylactoid reactions; serious skin reactions; hematologic toxicity; avoid in advanced renal disease.
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Hypersensitivity to ibuprofen or other NSAIDs; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in CABG surgery; active GI bleeding; history of recurrent peptic ulcer disease; severe heart failure.
Hypersensitivity to acetaminophen or any component of the formulation
Concurrent alcohol consumption increases risk of GI bleeding and ulceration. Avoid high-sodium foods to minimize fluid retention and potential exacerbation of hypertension. Grapefruit juice may slightly reduce rate of absorption but is not clinically significant.
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
Motrin (ibuprofen) is an NSAID. First trimester: Risk of miscarriage and congenital malformations, particularly cardiac defects, with use. Second trimester: Generally considered safer but avoid prolonged use due to potential for oligohydramnios. Third trimester: Contraindicated after 20 weeks due to risk of premature ductus arteriosus closure, oligohydramnios, and neonatal complications including pulmonary hypertension and renal impairment.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
Ibuprofen is excreted into breast milk in very small amounts. The M/P ratio is approximately 0.01. The relative infant dose is less than 1% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but avoid high doses or prolonged use.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
No dose adjustment is recommended in pregnancy; however, use should be restricted to the lowest effective dose for the shortest duration possible. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce plasma concentrations, but no formal dose adjustment studies exist. Avoid use after 20 weeks gestation.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
For acute pain, use lowest effective dose for shortest duration to minimize GI and renal risks. Administer with food or milk to reduce GI irritation. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min) or active peptic ulcer disease. Ibuprofen can mask fever, making infection detection difficult. Caution in asthma patients as it may precipitate bronchospasm. Monitor blood pressure in hypertensive patients due to potential for fluid retention.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Take with food or milk to prevent stomach upset.,Do not exceed 1200 mg per day for OTC use (adults) or as directed by your doctor.,Avoid alcohol while taking this medication to reduce risk of stomach bleeding.,Stop use and consult doctor if symptoms persist for more than 10 days (pain) or 3 days (fever).,Do not take with other NSAIDs or pain relievers without consulting your healthcare provider.,Notify your doctor if you have a history of heart disease, high blood pressure, or stomach ulcers.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MOTRIN vs INJECTAPAP, answered by our medical review team.
MOTRIN is a NSAID Analgesic that works by Non-selective COX-1 and COX-2 inhibitor, reducing prostaglandin synthesis.. INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MOTRIN and INJECTAPAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MOTRIN is: Ibuprofen (Motrin) 200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day for acute pain, and 2400 mg/day for chronic use.. The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MOTRIN and INJECTAPAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MOTRIN is classified as Category C. Motrin (ibuprofen) is an NSAID. First trimester: Risk of miscarriage and congenital malformations, particularly cardiac defects, with use. Second trimester: Generally considered sa. INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.